IShares Pharmaceuticals ETF Insiders
IHE Etf | USD 68.39 0.33 0.48% |
IShares Pharmaceuticals employs about 15 people. The company is managed by 15 executives with a total tenure of roughly 251 years, averaging almost 16.0 years of service per executive, having 1.0 employees per reported executive. Evaluation of IShares Pharmaceuticals' management performance can provide insight into the fund performance.
Geoffrey Flynn President Chief Operating Officer, Executive Vice President |
Robert Silver Executive Independent Trustee |
IShares |
IShares Pharmaceuticals Workforce Comparison
iShares Pharmaceuticals ETF is considered the top ETF in number of employees as compared to similar ETFs. The total workforce of Health category is currently estimated at about 30.0. IShares Pharmaceuticals totals roughly 15.0 in number of employees claiming about 50% of all ETFs under Health category.
iShares Pharmaceuticals Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. iShares Pharmaceuticals Price Series Summation is a cross summation of IShares Pharmaceuticals price series and its benchmark/peer.
IShares Pharmaceuticals Notable Stakeholders
An IShares Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as IShares Pharmaceuticals often face trade-offs trying to please all of them. IShares Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting IShares Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
George Parker | Independent Chairman of the Board of Trustees | Profile | |
Geoffrey Flynn | Chief Operating Officer, Executive Vice President | Profile | |
Matt Tucker | Vice President | Profile | |
Michael Latham | President Trustee | Profile | |
Amy Schioldager | Executive Vice President | Profile | |
Ira Shapiro | Vice President Chief Legal Officer | Profile | |
Jack Gee | Chief Financial Officer, Treasurer | Profile | |
Robert Silver | Independent Trustee | Profile | |
John Kerrigan | Independent Trustee | Profile | |
Madhav Rajan | Independent Trustee | Profile | |
Cecilia Herbert | Independent Trustee | Profile | |
Charles Hurty | Independent Trustee | Profile | |
Eilleen Clavere | Secretary | Profile | |
John Martinez | Independent Trustee | Profile | |
Robert Kapito | Trustee | Profile |
About IShares Pharmaceuticals Management Performance
The success or failure of an entity such as iShares Pharmaceuticals often depends on how effective the management is. IShares Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of IShares management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the IShares management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
The fund generally will invest at least 80 percent of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. US Pharmaceuticals is traded on NYSEARCA Exchange in the United States.
The data published in IShares Pharmaceuticals' official financial statements typically reflect IShares Pharmaceuticals' business processes, product offerings, services, and other fundamental events. However, there are additional fundamental indicators that are easier to understand and visualize along the underlying realities that are driving IShares Pharmaceuticals' quantitative information. For example, before you start analyzing numbers published by IShares accountants, it's essential to understand IShares Pharmaceuticals' liquidity, profitability, and earnings quality within the context of the iShares space in which it operates.
Please note, the presentation of IShares Pharmaceuticals' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, IShares Pharmaceuticals' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of IShares Pharmaceuticals' management manipulating its earnings.
When determining whether iShares Pharmaceuticals is a strong investment it is important to analyze IShares Pharmaceuticals' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact IShares Pharmaceuticals' future performance. For an informed investment choice regarding IShares Etf, refer to the following important reports: Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iShares Pharmaceuticals ETF. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in rate. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
The market value of iShares Pharmaceuticals is measured differently than its book value, which is the value of IShares that is recorded on the company's balance sheet. Investors also form their own opinion of IShares Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is IShares Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IShares Pharmaceuticals' market value can be influenced by many factors that don't directly affect IShares Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IShares Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if IShares Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IShares Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.